Research Peptide Supplier Scorecard for Canadian Buyers

Quick answer: what belongs in a research peptide supplier scorecard?#

A research peptide supplier scorecard is a structured way to compare Canadian research-material suppliers before a buyer relies on a catalogue page, certificate of analysis, or product claim. The scorecard should not ask, “Which site looks most polished?” It should ask whether the supplier can support a specific non-clinical research purchase with lot-level documentation, conservative claims, reachable support, and clear handling expectations.

A practical Canadian supplier scorecard should grade eight areas:

1. RUO boundary and claim discipline: whether the supplier avoids human dosing, disease-treatment claims, body-composition promises, cosmetic-result claims, testimonials, and protocol language.
2. COA quality: whether each material has a current, batch-specific certificate with lot number, test date, purity evidence, identity evidence, and lab attribution.
3. Lot traceability: whether the vial, order record, product page, and COA can be matched without detective work.
4. Analytical evidence: whether HPLC/UPLC purity and MS/LC-MS/MALDI identity are shown or available, not merely asserted.
5. Storage and vial controls: whether the supplier states storage temperature, light/moisture cautions, shipping expectations, fill amount, appearance, and retest or expiry guidance.
6. Support and document access: whether support can answer precise batch questions and provide missing records.
7. Catalogue clarity: whether product identity, salts/forms, blends, and related categories are described without conflating research mechanisms with outcomes.
8. Risk response: whether the buyer knows what to do when a supplier scores poorly.

This page gives a template, scoring scale, sample weights, red flags, and supplier questions. It is written for research-use-only procurement review. It is not medical advice, legal advice, dosing guidance, injection guidance, treatment guidance, cosmetic guidance, athletic-performance guidance, or a recommendation for personal use.

Before scoring a supplier that has not been reviewed before, send the research peptide supplier audit questionnaire. It turns the scorecard rows into precise questions about current-lot COAs, identity methods, lot mapping, unopened storage, shipping assumptions, document access, and RUO claim boundaries so the final score is based on saved answers rather than impressions.

When the supplier score hinges on analytical terms, do not let “HPLC tested,” “MS confirmed,” “sterile,” or “low endotoxin” sit as unexplained labels. Use the research peptide analytical methods glossary to translate each method into a scoreable evidence row: chromatographic purity, mass-based identity, current-lot traceability, contamination-control support, residual-solvent or water-content context, storage assumptions, and RUO claim boundaries. That keeps the scorecard from awarding full credit for scientific-looking words that do not answer the right quality question.

When a supplier scores well on basic identity and COA fields but the intended model is immune-, cytokine-, endothelial-, skin-barrier-, mitochondrial-stress-, or recovery-endpoint sensitive, add the research peptide sterility and endotoxin checklist. It keeps HPLC purity, sterility, bioburden, endotoxin, vial integrity, and RUO claim review in separate evidence rows so a clean-looking COA is not treated as a contamination-control package. For a brand-specific example, the expanded Lynx Labs documentation review applies the same supplier-scorecard logic to current product pages, batch documents, support paths, Canadian fulfillment records, ProductLink lane mapping, accept/clarify/quarantine/reject decisions, and RUO language.

After a supplier earns enough confidence to move from page review to shipment review, attach the research peptide import documentation checklist to the file. It covers the invoice, declared description, product-page capture, COA, vial-label photo, storage instructions, courier or border questions, and accept/quarantine/reject decision so a supplier score turns into a shipment-level record instead of a pre-purchase impression.

If the supplier has not earned a scored review yet, use the research peptide supplier red flag checklist first. It is the faster negative screen for stop signs such as human-use claims, no current lot-specific COA, missing identity confirmation, lot mismatch, storage silence, support drift, product-identity contradictions, and dead or stale product routes. A supplier score should not average those failures away.

If support answers a batch question, preserve that answer in the research peptide supplier response log template before changing the score. The scorecard says how much confidence the supplier earns; the response log shows which ticket, attachment, lot number, storage note, or RUO-boundary issue produced that confidence.

If the supplier loses points because COAs, storage guidance, shipping-temperature language, product-page claims, or lot mapping are unclear, send a narrow research peptide COA request email template pack and log the response before making the final score. Use the research peptide product page claims audit when the issue is the page's full impression: headline, FAQ, imagery, CTA, RUO footer, and whether the copy nudges readers toward human use. If a package arrives warm, delayed, wet, or undocumented, add the peptide temperature excursion log before accepting the supplier's storage score, then use the research peptide stability evidence matrix to decide whether the lot should be accepted, accepted with limitation, quarantined, rejected, or excluded from a sensitive endpoint. Once a supplier passes the scorecard, use the research peptide receiving SOP when the package arrives so the purchase decision becomes a lot-level receiving record, then move that evidence into the research peptide batch documentation template. If a lyophilised vial will be prepared as a working solution, route the next step to the peptide reconstitution record field matrix so solvent, concentration, vial label, storage, and freeze-thaw notes stay attached to the same lot. For recovery materials where supplier copy leans on pain, guarding, mobility, or injury-adjacent wording, add the nociception recovery peptide endpoint guide to the review so behavioural endpoints stay separate from human-use claims. The scorecard compares suppliers; the batch template preserves the specific product decision.

Downloadable-style template: the 100-point supplier scorecard#

Use this table as a worksheet. Assign a score in each row, keep notes, and attach supporting evidence such as COA screenshots, PDF file names, lot numbers, support emails, product-page dates, and storage instructions.

A supplier scoring 85-100 is relatively strong for documentation-first research procurement. A supplier scoring 70-84 may be usable only after missing records are requested and reviewed. A supplier scoring 50-69 should be treated as high-friction and high-uncertainty. A supplier scoring below 50 should not be relied on for serious research procurement without substantial remediation.

The score is not a certificate of safety. It is not a therapeutic endorsement. It is a way to avoid letting a clean website, a discount code, or one attractive purity number substitute for documented quality controls.

Download the CSV worksheet#

Use the research peptide supplier scorecard CSV when the review needs to move into a spreadsheet, procurement record, or shared QA folder. It includes the eight weighted rows, evidence fields, notes fields, cap-trigger prompts, subtotal line, and final decision line.

The download is intentionally plain. There are no hidden formulas, vendor rankings, affiliate preferences, or therapeutic claims. A reviewer can copy it into Excel, Google Sheets, Numbers, Airtable, Notion, or an internal procurement file and preserve the same RUO-first scoring logic from this page.

Save the completed file beside the COA PDF, product-page capture, support emails, vial-label photo, receipt condition notes, and batch documentation record. If a supplier changes a product page later, the saved worksheet should still show what evidence was reviewed at the time of the procurement decision.

Scoring calculator: convert row scores into a defensible decision#

The easiest way to make the scorecard reusable is to treat each row as a weighted score, not a yes/no impression. Use a 0-100 row confidence value, multiply it by the row weight, and add the weighted points.

Weighted points = row weight × row confidence ÷ 100
Final supplier score = sum of all weighted points, after applying any cap rules

Example:

Round the final score to the nearest whole number only after the review is complete. Do not round individual rows to make a supplier look stronger. If a cap-triggering red flag appears, apply the cap after the subtotal. A supplier with a calculated score of 86 but non-batch-specific COAs should not be called an 86-point supplier; the cap should pull the result down until the missing evidence is resolved.

For citations, use the plain-language label Canadian research peptide supplier scorecard rather than a brand claim like “best peptide supplier.” That anchor is safer, more accurate, and easier for procurement, lab operations, and quality-assurance readers to understand.

2026 scorecard refresh: cap rules, evidence grades, and review cadence#

The 2026 update turns this page from a generic checklist into a reusable linkable asset. The most important change is that the scorecard now separates row confidence, cap triggers, and review cadence. Those three fields stop a supplier from looking better than the underlying evidence supports.

Use this sequence before assigning a final supplier score:

1. Grade each row from 0-100 confidence. The row score should describe the evidence actually saved, not the reviewer’s general impression.
2. Multiply by the row weight. A 70-confidence COA row with a 20-point weight contributes 14 points, not 70 points.
3. Apply cap rules after the subtotal. A supplier with polished support and fast shipping still cannot score as strong if the COA is representative, missing dates, or not tied to the current lot.
4. Record the evidence grade. Use A/B/C/D/F to show whether the supporting file is complete, partial, weak, contradictory, or absent.
5. Set a next-review date. Supplier trust expires when lots rotate, pages change, support policies shift, or a new product category is added.

For recurring supplier review, do not overwrite old scores. Add a dated row for each review. A supplier can improve after adding lot-specific COAs, tighter RUO language, better storage notes, or clearer support paths. It can also degrade after a product-page rewrite, fulfillment change, or catalogue expansion. The scorecard is useful because it preserves the trajectory, not because it pretends one score lasts forever.

2026-05 worksheet upgrade: hard caps before averages#

The May 2026 refresh adds a stricter rule to the downloadable worksheet: apply hard caps before comparing final scores. A supplier should not look strong because it has fast shipping, a polished catalogue, and responsive support while the one evidence row that matters most is weak. If the COA is generic, the product page gives human-use guidance, or the lot cannot be matched, the subtotal is no longer the final decision.

Use this cap map when filling out the CSV:

This is deliberately harsher than a normal checklist. In research procurement, averaging can hide the exact failure that later makes a result uninterpretable. A supplier with a 92-point website experience and a non-lot-specific COA is not a 92-point supplier. It is a capped supplier until the batch record is fixed.

The CSV now includes separate fields for row confidence, evidence grade, cap trigger, cap value, decision status, packet location, and next review date. Keep those fields boring and literal. “Looks reputable” is not evidence. “COA file SEM-2409A.pdf matches product page lot SEM-2409A, captured 2026-05-22” is evidence.

Category addenda: when the scorecard needs stricter rows#

The base scorecard works across the Northern Compound archive, but some categories need extra scrutiny before a supplier comparison is useful.

These addenda do not change the RUO boundary. They make the scorecard harder to game in categories where search demand pulls supplier pages toward consumer promises. The scorecard should reward suppliers that make current batch evidence easy to inspect and penalize suppliers that blur research documentation with outcome marketing.

Why a scorecard beats a simple “best supplier” list#

Most “best peptide supplier” pages collapse different questions into one ranking. They mix price, shipping speed, catalogue size, user anecdotes, affiliate incentives, and vague trust language. That format is weak for research buyers because it hides the actual evidence.

A scorecard is better because it creates a visible audit trail. If Supplier A wins because it publishes current lot-specific COAs and answers documentation questions clearly, the reader can see that. If Supplier B loses points because it uses aggressive human-outcome language while hiding batch records, the reader can see that too. The scorecard turns trust into a set of inspectable claims.

This matters across compound categories. A buyer looking at broad research peptides may start with a category page for where to buy research peptides in Canada. A buyer comparing incretin-pathway research materials may look at Semaglutide, Tirzepatide, Retatrutide, or Cagrilintide. A buyer focused on recovery models may compare BPC-157, TB-500, and BPC-157 + TB-500 blend; when the fixed blend is the candidate, the BPC-157 + TB-500 blend supplier checklist adds the ratio, dual-identity, and attribution checks a generic supplier scorecard does not fully cover. A skin-research buyer may review GHK-Cu, LL-37, or KPV. The compound changes, but the evidence standard should not disappear.

A supplier scorecard also keeps compliance risk visible. If a page makes human-use claims, that should reduce the score even if the COA looks polished. Strong analytical documentation does not cancel weak claims.

Step 1: score the RUO boundary before the COA#

Start with the claims environment. A supplier that cannot keep its public copy inside research-use-only boundaries creates risk before the buyer even reaches the COA.

Award full points when the supplier:

• uses clear research-use-only language;
• avoids dosing, administration, injection, cycle, treatment, cure, diagnosis, prevention, athletic-performance, tanning, cosmetic-result, or body-transformation claims;
• avoids personal-use testimonials and before/after imagery;
• distinguishes research mechanisms from expected outcomes;
• avoids implying that a product is appropriate for humans because a study exists; and
• routes readers toward documentation and batch verification rather than protocols.

Deduct points when the site uses “for research only” language in one place but surrounds it with personal-use cues. A product page can say RUO and still be weak if it talks like a clinic, gym forum, or cosmetic-results page. A research buyer should not treat disclaimers as magic words. The whole page should respect the boundary.

This is especially important for categories with high consumer demand. Incretin-pathway compounds, skin peptides, growth-hormone secretagogues, recovery peptides, and cognitive peptides all attract non-research search traffic. A supplier that chases that traffic with human outcome claims is harder to trust as a research-material source.

For a deeper claims review, pair this scorecard with the research-use-only compliance checklist. That companion asset focuses on page language, disclosure structure, and red-flag wording.

Step 2: score the COA as a batch document, not a badge#

A certificate of analysis should connect a specific material to a specific batch. It should not function as decorative proof that “testing happened somewhere.”

Give the highest score when the COA includes:

• peptide name and, where useful, sequence, formula, salt/form, or molecular weight;
• lot or batch number that matches the vial/order record;
• test date and retest or expiry guidance;
• HPLC or UPLC purity result;
• chromatogram or peak table;
• mass-spectrometry identity evidence such as MS, LC-MS, or MALDI-TOF;
• expected and observed mass where available;
• fill amount or concentration/form description;
• storage conditions;
• lab, analyst, reviewer, or testing-source attribution; and
• document version or file date.

Deduct heavily when a supplier shows a single generic PDF for many batches, crops out identifiers, hides the test date, or claims very high purity without any trace detail. A purity number alone is not enough. HPLC purity and mass-spectrometry identity answer different questions. A strong score requires both composition evidence and identity evidence.

The companion peptide COA verification checklist gives a deeper row-by-row audit process, including a five-minute triage workflow and an accept/clarify/quarantine/reject decision tree. Use that checklist when a supplier is close enough to merit a full document review.

Step 3: match the lot before trusting the product page#

Lot traceability is the simplest place to catch weak suppliers. The buyer should be able to connect:

• product page;
• downloadable COA;
• vial label;
• packing slip or order record;
• support response if clarification is needed; and
• internal research inventory record.

If those identifiers do not match, the supplier may still be able to explain the mapping, but the score should drop until the explanation is documented. A representative COA is not the same as a current batch-specific COA. A document from a previous lot may show that the supplier has tested a material before, but it does not prove the current vial has the same profile.

This is not bureaucratic nitpicking. Research endpoints can be affected by model design, assay conditions, storage, operator technique, reagent quality, and material variation. Lot traceability helps keep those variables from being blurred together.

A high-scoring supplier makes traceability boring. The same identifier appears where it should. Support can answer quickly. The buyer does not need to infer that a PDF belongs to the current batch.

Step 4: score storage, vial condition, and shipping evidence#

Peptide procurement does not end at identity and purity. Materials can be affected by moisture, light, temperature excursions, repeated freeze-thaw events, oxidation, aggregation, vial seal problems, and unclear receipt conditions. A supplier that gives no handling guidance should lose points even if its COA looks acceptable.

Look for documentation on:

• lyophilized appearance;
• fill amount;
• vial and closure description;
• storage temperature before receipt;
• storage temperature after receipt;
• light and moisture cautions;
• shipping method and expected temperature exposure;
• retest or expiry guidance;
• what to do if a vial arrives warm, cracked, wet, unlabeled, or inconsistent; and
• whether cold-chain expectations differ by material.

A buyer reviewing SS-31, MOTS-c, NAD+, or Selank may care about different research models than a buyer reviewing GHK-Cu or BPC-157. But each case still needs storage and receipt documentation.

Use the peptide storage and vial inspection checklist after supplier selection, especially when a package arrives with ambiguous condition, damaged packaging, unclear labels, or missing records.

Step 5: test supplier support with precise questions#

Support quality is part of supplier quality. The fastest way to test it is to ask specific documentation questions before relying on a page.

Use questions like these:

1. Is the COA on this page batch-specific to the material currently shipping?
2. What lot number should appear on the vial and packing record?
3. Can you provide the HPLC chromatogram or peak table for this lot?
4. Can you provide MS, LC-MS, MALDI-TOF, or equivalent identity evidence?
5. What is the expected molecular mass and observed mass for this lot?
6. What storage conditions apply before and after receipt?
7. Is the material tested in-house, by a third-party analytical lab, or both?
8. Does the COA include fill amount, appearance, and test date?
9. If the vial label and PDF lot number differ, how are they mapped?
10. Can you confirm that the product is research-use-only and not intended for human or veterinary use?

High-scoring support answers the question asked, provides documents when appropriate, and does not drift into human-use advice. Low-scoring support sends generic assurances, refuses to clarify lot numbers, or starts discussing personal protocols. If a support channel gives dosing or administration guidance, that is a serious compliance red flag.

Step 6: compare category pages without letting one product carry the whole supplier#

One excellent product page does not prove the whole catalogue is well controlled. A scorecard should sample multiple pages across categories.

For a broad Canadian supplier review, inspect at least:

• one recovery-related material, such as BPC-157 or TB-500;
• one weight-management or incretin-pathway research material, such as Semaglutide or Tirzepatide;
• one skin or barrier research material, such as GHK-Cu or KPV;
• one cognitive or stress-modulation research material, such as Selank, Semax, or DSIP; and
• one mitochondrial or healthy-ageing research material, such as SS-31, MOTS-c, or Epitalon.

The goal is not to buy everything. The goal is to see whether the supplier’s documentation standard is systematic or isolated. A supplier that documents high-demand pages but neglects lower-volume materials may have uneven quality controls. A supplier that maintains clear COAs, conservative copy, and storage guidance across categories deserves a higher score.

Category sampling matrix for Canadian peptide suppliers#

A supplier scorecard becomes stronger when it samples more than one catalogue lane. The point is not to force a buyer into every category. The point is to check whether documentation quality is a habit or a showcase on one high-demand page.

Use this sampling matrix when comparing broad Canadian research peptide suppliers:

For each lane, record whether the supplier's documentation standard is consistent. A supplier that publishes detailed COAs for popular incretin materials but gives vague PDFs for cognitive or skin compounds should not receive a catalogue-wide high score. Score the supplier as a system, then score the selected batch as a material.

Evidence packet: what to capture before the page changes#

A supplier score is only useful if the supporting evidence is saved. Product pages change, COAs get replaced, lots rotate, and support answers disappear into inboxes. Treat the scorecard as an index to an evidence packet rather than a standalone opinion.

A complete evidence packet should include:

This packet does not prove a peptide is safe or suitable for human use. It simply makes the procurement review auditable. If a lab later sees an unexpected assay result, the evidence packet helps separate supplier uncertainty from model design, storage history, operator variation, and endpoint interpretation.

Supplier scorecard versus COA checklist versus batch record#

Northern Compound now has several procurement assets because each one answers a different question. Do not flatten them into one generic checklist.

The workflow should move from supplier-level trust to lot-level evidence. A supplier can have a strong general score and still ship a weakly documented lot. A supplier can also improve after a missing document is requested. The scorecard is a starting gate, not a permanent label.

Decision rules: accept, clarify, quarantine, or reject#

Use the final score with explicit decision rules. This prevents a borderline supplier from sliding through because the page looks polished or the material is hard to source.

For Canadian buyers, “clarify” is often the most useful middle state. It keeps the review fair without pretending uncertainty is acceptable. A supplier that responds with current, specific records may recover points. A supplier that responds with vague assurances, human-use advice, or unrelated marketing copy should lose points.

Copy-paste supplier audit worksheet#

Use this worksheet when you need a portable version of the scorecard for a procurement note or internal review. Keep the language factual and evidence-based.

Supplier name:
Supplier URL:
Date reviewed:
Reviewer:
Intended research category:
Representative products/pages sampled:

RUO boundary and claims (0-15):
Evidence saved:
Concerns:

Batch-specific COAs (0-20):
Lots reviewed:
Methods visible:
Missing details:

Lot traceability (0-10):
Vial/order/COA identifiers:
Mapping issues:

Analytical detail (0-15):
Purity evidence:
Identity evidence:
Expected/observed mass if available:

Storage and handling documentation (0-10):
Storage condition:
Shipping/temperature language:
Vial/appearance/fill notes:

Supplier support (0-10):
Questions sent:
Answers received:
Human-use or protocol drift:

Catalogue transparency (0-10):
Forms, salts, blends, category clarity:
Broken/dead/unclear pages:

Canadian buyer practicality (0-10):
Shipping/document access/contact clarity:
Return/replacement or discrepancy process:

Caps applied:
Final score:
Decision: accept / clarify / quarantine / reject
Follow-up owner and date:
Evidence packet location:

This worksheet is deliberately plain. It is easier to reuse, cite, and audit than a decorative PDF that hides the reasoning. If a supplier or internal reviewer disagrees with the score, the dispute should be about a specific row and a specific record.

Spreadsheet-ready supplier scorecard columns#

If the scorecard is being used by a lab manager, procurement lead, or affiliate-review editor, put the review into a spreadsheet rather than a private note. A spreadsheet makes weak suppliers harder to hide because every score needs a source cell.

Use these columns as the portable schema:

supplier_name
supplier_url
review_date
reviewer
catalogue_lane
sampled_product_urls
sampled_lot_numbers
ruo_boundary_score_0_to_15
ruo_boundary_evidence
coa_score_0_to_20
coa_lot_match
coa_test_date
coa_purity_method
coa_identity_method
coa_trace_visible
lot_traceability_score_0_to_10
vial_order_coa_match
analytical_detail_score_0_to_15
storage_handling_score_0_to_10
support_score_0_to_10
support_questions_sent
support_answer_quality
catalogue_transparency_score_0_to_10
canadian_buyer_practicality_score_0_to_10
cap_trigger
cap_value
subtotal_before_cap
final_score
decision
follow_up_needed
evidence_packet_location
next_review_date

The important field is not the final score. It is the evidence column beside each score. A row reading coa_score_0_to_20 = 18 should point to a current lot-matched COA, not to a vague memory that a certificate was visible. A row reading support_score_0_to_10 = 9 should point to the exact question and exact answer, not to a general impression that support seemed helpful.

For repeat supplier reviews, add one row per supplier per review date. Do not overwrite the previous review. Supplier pages, COAs, lots, support policies, and product claims can change. A dated row preserves whether the supplier improved, degraded, or stayed consistent over time.

Evidence threshold matrix by review type#

Not every buyer needs the same depth of review, but every review needs a visible minimum. Use this threshold matrix to prevent the scorecard from becoming either too casual or too bureaucratic.

For Northern Compound-style editorial use, the last row matters most. A public article can cite the scorecard as a standard for reviewing suppliers, but it should not imply that a supplier is approved for human use. The safe phrasing is: “use a Canadian research peptide supplier scorecard to compare COA quality, lot traceability, RUO claims, and storage documentation.” The unsafe phrasing is: “this supplier is safe,” “this peptide works,” or “this is the best supplier for treatment.”

Review-expiry rules: when to re-score a supplier#

A supplier score should expire. It is a snapshot of a claim environment, a document set, and a batch-documentation workflow at one point in time. Treating a score as permanent is one of the easiest ways to turn a useful worksheet into stale trust.

Use this review-expiry matrix when the scorecard is part of a recurring procurement file, a public editorial citation, or a multi-supplier comparison:

For most active suppliers, a quarterly review cadence is a reasonable default. For high-demand or fast-changing categories such as incretin-pathway materials, skin peptides with cosmetic-search pressure, or cognitive peptides with route-of-use overclaiming risk, use shorter review windows whenever the product page, COA, or support path changes. For an inactive supplier that is only being mentioned as a documentation example, re-score before citation rather than on a calendar.

The worksheet should record the next review date and the trigger that would force an earlier review. That makes the scorecard auditable without pretending a Canadian research peptide supplier earns permanent trust from one clean review.

Scorecard-to-outreach citation block#

This asset is built to be cited by procurement, lab-operations, QA, research-methods, and cautious buyer-intent pages. If someone needs a short citation or link description, use this language:

Northern Compound's Canadian research peptide supplier scorecard is a research-use-only procurement worksheet for comparing suppliers by RUO claim discipline, batch-specific COAs, lot traceability, analytical evidence, storage documentation, support quality, and Canadian buyer workflow. It is not a safety endorsement, therapeutic recommendation, or dosing guide.

Suggested citation anchors:

• Canadian research peptide supplier scorecard
• research peptide supplier scorecard
• peptide supplier audit checklist
• batch-specific COA supplier review
• RUO peptide supplier checklist
• Canadian peptide procurement worksheet

Avoid anchors that imply medical, personal-use, or “best supplier” endorsement. The point of this page is to make trust claims auditable, not to create another thin affiliate ranking.

Red flags that should cap the supplier score#

Some problems are serious enough that they should cap the total score even if other rows look strong.

Cap the score at 70 if:

• COAs are present but not batch-specific;
• support must manually explain every lot mapping;
• storage guidance is generic and incomplete;
• product pages are mostly compliant but contain occasional human-use wording; or
• analytical details are named but not visible.

Cap the score at 50 if:

• the supplier uses disease, treatment, dosing, cycle, or body-transformation language;
• COAs lack lot numbers or dates;
• support refuses to answer documentation questions;
• product pages present purity percentages without identity testing; or
• the catalogue contains many broken product links or unclear forms.

Cap the score at 30 if:

• the supplier gives human dosing or administration advice;
• documents appear copied, cropped, mismatched, or impossible to connect to current batches;
• the site uses fake-looking testimonials or before/after claims;
• product identity is unclear; or
• there is no credible route to obtain batch documentation.

These caps prevent a supplier from offsetting critical failures with cosmetic strengths. Fast shipping does not compensate for aggressive claims. A good price does not compensate for missing identity evidence. A polished product page does not compensate for no lot traceability.

How to use the scorecard in a procurement workflow#

For a practical workflow, use four passes.

Pass 1: screen the page. Read the supplier’s category and product pages. Remove any supplier that clearly pushes human use, dosing, disease claims, or transformation claims. Do not waste time scoring documents for a supplier whose public claims already fail the RUO boundary.

Pass 2: review batch evidence. Download or request the COA for the exact material and lot under consideration. Use the COA checklist to score analytical support. Confirm that purity, identity, lot number, test date, and storage guidance are present.

Pass 3: inspect logistics and receipt controls. Review shipping, storage, vial condition, and support language. Use the storage/vial checklist when the package arrives or when a supplier’s handling guidance is vague.

Pass 4: document the decision. Save the scorecard, COA, support emails, product-page URL, date reviewed, and notes. If the material is used in a research context, record the supplier score with the batch record so future interpretation does not depend on memory.

This workflow is intentionally conservative. It is easier to loosen standards later than to reconstruct documentation after a batch has been used, a page has changed, or a supplier has rotated stock.

Example scoring notes#

Here is a sample note style that keeps a review auditable without turning it into a novel:

The note does not claim the product is safe, effective, or suitable for human use. It documents why the supplier passed or failed a research procurement screen.

Adjust the weighting by research risk#

The 100-point version above is a strong default, but not every procurement question carries the same documentation burden. A buyer comparing a low-volume exploratory material should still care about COAs and RUO language, but a buyer planning a multi-batch study, a cross-site comparison, or a long storage interval should weight traceability and storage more heavily.

Use these adjustments when the research context is more demanding:

Do not lower the RUO boundary score for any scenario. Claim discipline is not optional because the material is familiar, popular, or widely discussed. If a supplier drifts into human-use language, the score should fall even when the analytical record is otherwise attractive.

For broad category reviews, keep the default weighting. For a specific study, add a short note explaining why any row was reweighted. That note makes the scorecard easier to interpret later when someone asks why two suppliers with similar COAs received different final scores.

How to compare two suppliers without overfitting the score#

A scorecard can create false precision if the buyer treats a one-point difference as meaningful. Supplier A scoring 82 and Supplier B scoring 84 are functionally similar unless the difference comes from a critical row. The better question is where the gap appears.

Use this comparison sequence:

1. Eliminate hard fails first. Remove any supplier with human-use claims, no batch-specific COAs, no lot traceability, or support that gives protocol-style advice.
2. Compare the weakest row, not only the total. A supplier with a high total but a poor storage score may be risky for temperature-sensitive materials.
3. Look for consistency across categories. A supplier that documents Semaglutide well but neglects Selank, GHK-Cu, or SS-31 may have uneven processes.
4. Request clarification before rejecting a near miss. Missing retest dates, unclear lab attribution, or limited method summaries may be fixable if support responds with current records.
5. Document why the winner won. The scorecard should say which evidence changed the decision, not just which supplier had the highest total.

This prevents the worksheet from becoming spreadsheet theatre. The goal is a defensible procurement decision, not a fake ranking system.

What to save with the completed scorecard#

A completed scorecard is most useful when it sits beside the evidence it summarizes. Save the review as a small packet:

• completed scorecard with date and reviewer;
• product page URL and capture date;
• COA PDF or screenshot with file name;
• lot number and vial label photo if available;
• support emails or chat transcript;
• storage/shipping instructions;
• receipt-condition notes;
• internal research inventory identifier; and
• decision note explaining whether the supplier was accepted, rejected, or held pending clarification.

This record matters because supplier pages change. COAs get replaced. Lots sell through. Support answers may differ between batches. If a research team needs to interpret results six months later, “the page looked fine” is not a useful audit trail. A saved scorecard packet gives the team a concrete record of what was known at the time.

For the broader folder structure, use the research peptide supplier due diligence packet. It turns the scorecard into a complete supplier file: page captures, COAs, analytical-method notes, support transcripts, storage policies, receiving pointers, decision language, and review-expiry dates.

For recurring purchases, repeat the scorecard at the lot level rather than assuming the supplier remains unchanged. A supplier can improve its documentation, weaken its copy, change fulfillment partners, rotate testing labs, or add new catalogue pages that do not meet the same standard. Supplier trust should be maintained, not inherited permanently.

Common scoring mistakes#

The most common mistake is giving too much credit for a clean website. Good design can improve usability, but it does not prove the material is documented. A supplier should earn points through records, traceability, and claim discipline.

Other mistakes include:

• treating a purity percentage as a complete COA;
• accepting a representative certificate as if it documents the current lot;
• ignoring storage language until after the package arrives;
• letting fast shipping offset weak analytical evidence;
• assuming a supplier is compliant because one page says research-use-only;
• scoring a product page without saving the version reviewed;
• using customer anecdotes as quality evidence;
• failing to ask support precise questions; and
• comparing prices before eliminating documentation failures.

A good scorecard makes those mistakes harder. It slows the buyer down at exactly the points where the market tries to speed them up.

One-page field checklist#

If the full worksheet is too much for a first pass, use this condensed field checklist. A supplier that cannot pass these questions should not move to price comparison.

This condensed version is useful for a first screen, but it should not replace the full scorecard for a supplier that will be used repeatedly, cited publicly, or compared across multiple peptide categories.

References and standards worth knowing#

The scorecard borrows from quality-system thinking without pretending that RUO peptide suppliers are equivalent to licensed drug manufacturers. The useful principles are traceability, risk management, analytical support, and reliable records.

Authoritative references that support this approach include:

• Health Canada Good manufacturing practices guide for drug products (GUI-0001), for quality-system and documentation principles in regulated drug contexts.
• Health Canada guidance on certificates of pharmaceutical products and GMP certificates (GUI-0024), for how regulated certificate language connects to site/product claims.
• Standards Council of Canada Good Laboratory Practices, for the role of quality systems in non-clinical data generation.
• OECD Principles on Good Laboratory Practice, for the quality and validity of non-clinical test data.
• ISO/IEC 17025 testing and calibration laboratories, for laboratory competence and reliable testing concepts.
• USP Reference Standards, for why characterized reference materials matter in analytical testing.
• ICH Q9(R1) Quality Risk Management, for risk-based thinking when missing evidence, documentation uncertainty, or supplier-process gaps should change a decision.

These references do not make a research peptide supplier “approved.” They simply give buyers a vocabulary for asking better questions about evidence, traceability, documentation quality, and risk-based supplier review.

Supplier scorecard FAQ#

Bottom line#

A Canadian research peptide supplier should not win trust by having the loudest claims, the cleanest product photos, or the lowest price. It should win by making evidence easy to inspect.

Use this scorecard to compare suppliers on the things that matter for research procurement: RUO discipline, batch-specific COAs, lot traceability, analytical evidence, storage documentation, support quality, and practical Canadian buyer workflows. Then keep the completed scorecard with the COA and receipt records so the decision remains auditable later.

If a supplier cannot answer basic batch questions, do not let marketing language fill the gap. Move back to the evidence.